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Purpose: Arylpiperazines have been recognized as the largest and most diverse class of compounds 
exerting actions on the central nervous system with strong affinity for serotonin and dopamine receptors. 
We here report the synthesis of some novel arylpiperazines and their evaluation for possible 
antipsychotic properties. 
Methods: The target compounds 2-[4-(aryl substituted) piperazin-1-yl]-N-phenylacetamides (3a-j) were 
synthesized by first reacting aniline (1) in 2 N sodium hydroxide with chloroacetylchloride in 
dichloromethane to obtain 2-chloro-N-phenylacetamide (2) and subsequently treating with appropriate 
phenylpiperazine in acetonitrile in the presence of K2CO3 and KI. All the compounds were characterized 
by analytical and spectroscopic methods. The compounds were evaluated for antipsychotic activity 
using three animal models. 
Results: All the 10 new arylpipeazines showed variable antipsychotic activity with compound 3h being 
the least effective in the induction of catalepsy. Their effect may involve interaction with 5-HT2A and D2 
receptors. 
Conclusion: A synthetic method and possible antipsychotic effect have been established for 2-[4-(Aryl 
substituted) piperazin-1-yl]-N-phenylacetamides.   
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INTRODUCTION 
 
Schizophrenia is a complex psychological 
disorder affecting about 1 % of the population 
worldwide [1,2]. The use of classical 
neuroleptics such as phenothiazines and 
butyrophenones for the treatment of 
schizophrenia is associated with severe 
mechanism-related side effects including 
induction of acute extrapyramidal symptoms. 
They all share the ability to block D2 
dopamine receptors and effectiveness in the 
treatment of positive symptoms of 
schizophrenia [3,4]. The adverse effects 
presented by classical antipsychotics, along 
with their ineffectiveness in the treatment of 
negative symptoms of schizophrenia has 
encouraged the search for other drugs [5]. 
Both serotonergic and dopaminergic systems 
have been proposed to be involved in the 
mechanism of action of antipsychotic drugs. 
Most atypical antipsychotic drugs have in 
common relatively strong blockade of 5-HT2A 
receptors coupled with weaker antagonism of 
the D2 receptors [6, 7]. This so-called 
“serotonin-dopamine hypothesis” has 
become the basis for developing new 
antipsychotics with the view to achieving 
superior efficacy with a lower incidence of 
extrapyramidal side effects compared to 
earlier drugs . Molecules based on 
arylpiperazine core were classified as ligands 
of serotonin (5-HT), dopamine and 
adrenergic receptors and some of them 
became clinically useful drugs in the 
treatment of anxiety, depression and 
psychiatric disorders [8]. Long-chain 
arylpiperazines have been (LCAPs) 
recognized as the largest and most diverse 
classes of compounds exerting actions on the 
central nervous system particularly serotonin 
and dopamine affinity [9,10]. Their general 
chemical structure consists of the 
arylpiperazine moiety connected by an alkyl 
chain with the terminal amide or imide 
fragment. As part of our ongoing work on the 
development of strategies for the preparation 
of new antipsychotics, we here report the 
synthesis of some novel amide 





Melting points of the synthesized compounds 
were determined by open capillary method 
and are uncorrected. The infrared (IR) 
spectra of synthesized compounds were 
recorded in potassium bromide discs on 





NMR (nuclear magnetic resonance) spectra 
were recorded on a Bruker DRX-300 
spectrophometer (
1
H at 300 MHz and 
13
C at 
75 MHz) in CDCl3 containing TMS as an 
internal standard. Elemental analyses were 
performed on Elementar Vario EL III 
analyzer. The electrospray mass spectra 
were recorded on a Thermo Finnigan LCQ 
Advantage Max ion trap mass spectrometer. 
All reagents were of commercial quality and 
were used without further purification. The 
reaction’s progress was monitored by thin-
layer chromatography (TLC) using silica gel 
G and spots were visualized in an iodine 
chamber.  
 
Synthesis of 2-Chloro-N-phenylacetamide 
(2) 
 
Aniline 1 (3.65 ml, 0.04 mol) in 2N aqueous 
sodium hydroxide (150 ml) at room 
temperature was treated with 
chloroacetylchloride (3.18 ml, 0.04 mol) as a 
solution in dichloromethane (100 ml). After 1 
h, the layers were separated and the 
aqueous phase extracted with additional 
portion of dichloromethane (100 ml). The 
organic phase was combined, washed with 
an aqueous solution of 1N HCl, saturated 
NaHCO3, dried with Na2SO4, and 
concentrated to afford 2. Yield: 68.12 %; 
m.p.:  130-132 
o
C; IR (KBr, cm
-1
): 3311, 
3021, 2862, 1681, 1217, 769, 670; 
1
H NMR 
(300 MHz; CDCl3 δ): 4.19 (s, 2H), 7.11-7.39 
(m, 3H, Ar-H), 7.53 (d, J= 7.8, 2H, Ar-H), 8.24 
(br, s, 1H). Anal.Calcd.for C8H8ClNO: C, 
56.65; H, 4.75;  N, 8.26; Found: C, 56.59; H, 
4.66; N, 8.18.  
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General procedure for the synthesis of 3a-j 
 
2-Chloro-N-phenylacetamide 2 (0.84 g, 0.005 
mol) was dissolved in acetonitrile (100 ml) in 
a 250 ml Round bottom flask. Anhydrous 
K2CO3 (0.69 g, 0.005 mol), catalytic amount of 
potassium iodide and appropriate 
arylpiperazine (0.005 mol) were added into 
above solution. The above mixture was 
allowed to reflux with continuous stirring on 
magnetic stirrer for 12 h. After completion of 
reaction, the solvent was removed by 
vacuum distillation and the residue dissolved 
in chloroform and water. The separated 
organic layer was washed with brine and 
dried over anhydrous magnesium sulphate. 
Removal of the solvent under vacuum 
afforded the crude product which was 
recrystallized from ethanol to obtain crystals 




Swiss albino mice (six in each group) of 
either sex (20 - 25 g) were housed per cage 
in standard laboratory conditions (12 h 
light/dark cycle, 22±2
 o
C room temperature). 
Food and water were available to them ad 
libitum. The animal experiments were 
approved by institutional ethical committee. 
 
Apomorphine-induced mesh climbing 
assay  
 
Each mouse was placed in a cylindrical wire 
mesh cage (height 13 cm, diameter 14 cm 
and mesh size 3mm) for 1h prior to the 
experiments. Mice in the test, control and 
standard groups were injected respectively 
with test compounds (EDmin 20 mg/kg), 
normal saline and clozapine intraperitoneally 
and returned to the home cage. After 30 min, 
apomorphine (2.5 mg/kg, i.p.) was injected. 
Mesh climbing behavior was assessed at 5 
min intervals for up to 20 min, starting 10 min 
after the apomorphine administration using 
the following scoring system: 0-no paws on 
the cage, 1-one paw on the cage, 2-two paws 
on the cage, 3-three paws on the cage, 4-four 
paws on the cage. The score recorded for 
each animal was based on the position of the 
animal at the moment it was first observed. 
The maximum possible score was 20. 
Recording was undertaken by an observer 
who was unaware of the specific drug 
treatments [11]. 
 
Antagonism of 5-hydoxytryptophan (5-
HTP) induced head twitches  
 
The head twitches were measured after 
placing a mouse in a Perspex cage for a 30 
min habituation period. The mice were then 
injected with pargyline (75 mg/kg, i.p.) in 
order to prevent the rapid degradation of 5-
HTP. Thirty minutes later, the test compound 
(EDmin 20 mg/kg, i.p) was administered. After 
a further 30 min, the mice received 5-HTP 
(50 mg/kg, i.p.) and then returned to the test 
cages. Twenty minutes after 5-HTP 
injections, head twitches were assessed 
every 10 min for 30 min. The head twitches 
were monitored using the following scoring 
system, 0- absent, 1-moderate, 2-marked. 
The maximum possible score was 8. An 
observer made all observations unaware of 




Catalepsy was induced in albino mice (n=6) 
with haloperidol (1.0 mg/kg, i.p.) and was 
assessed at 30, 60, 90, 120, and 240 min by 
means of a standard bar test. Catalepsy was 
assessed in terms of the time (sec) for which 
the mouse maintained an imposed position 
with both front limbs extended and resting on 
a 4 cm high wooden bar (1.0 cm diameter). 
The endpoint of catalepsy was considered to 
occur when both front paws were removed 
from the bar or if the animal moved its head 
in an exploratory manner. Severity of the 
cataleptic behavior was given a score of 1 if 
the animal maintained the imposed posture 
for at least 20 s and every additional 20 sec 
one extra point would be given. A cut-off time 
of 1100 s was applied during the recording of 
observations. The animals were returned to 
their individual home cages in between 
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Figure 1: Synthesis of the target compounds. Reagents and condition: (i) NaOH; dichloromethane (ii) 
acetonitrile, K2CO3, KI. 
 
determinations. All observations were made 
between 10.00 and 16.00 hrs in a quiet room 
at 23-25ºC. The animals in the test group 
were administered with test drug (EDmin 80 
mg/kg, i.p.) instead of haloperidol and the 
remaining procedure for assessment of 





The results are expressed as mean ± SEM. 
Statistical analysis of the results in the test 
group was carried out by comparison with the 
results in the control group, employing non-
parametric Kruskal Wallis test or one-way 
ANOVA (Jandel Sigmastat version 2.0). The 





The reactions are outlined in Figure 1 and the 





Yield: 66%; m.p.: 124-125 
o
C; IR (KBr, cm
-1
): 
3311, 3016, 2829, 1683, 1221, 1017, 759;          
1
H NMR (300 MHz; CDCl3 δ): 2.65 -2.68 (m, 
4H), 2.96-3.16 (m, 4H), 3.18 ( s, 2H, COCH2), 
6.83 -6.91 (m, 3H, Ar-H), 7.09 -7.32 (m, 5H, 
Ar-H), 7.56 (d, J=7.5, 2H ), 9.10 (br s,1H);         
13
C NMR ( 75 MHz, CDCl3 δ): 48.9, 53.0, 
76.5, 115.3, 116.6, 119.6, 123.8, 128.7, 
128.8, 137.2, 150.6, 167.7; MS (EI) m/z: 
296.3 (M+1). Anal.Calcd. for C18H21N3O: C, 
73.19; H, 7.17; N, 14.23. Found: C, 72.98; H, 
6.34; N, 14.03.  
 
Table1: Substituents of compounds 3a-j 
 
Compd no. Compd code  R 
1 3a H 
2 3b 3-CH3 
3 3c 4-CH3 
4 3d 2-OCH3 
5 3e 3-OCH3 
6 3f 4-OCH3 
7 3g 2-Cl 
8 3h 3-Cl 
9 3i 4-F 
10 3j 4-NO2 
 
2-[4-(3-Methylphenyl) piperazin-1-yl]-N-
phenylacetamide (3b)  
 
Yield: 62%; m.p.: 92-94 
o
C; IR (KBr, cm
-1
): 
3307, 3016, 2829, 1682, 1219, 1016, 766; 
1
H 
NMR (300 MHz; CDCl3 δ): 2.29 (s, 3H), 2.78 -
2.81 (m, 4H), 3.11-3.32 (m, 4H), 3.21 ( s, 2H, 
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COCH2), 6.85-6.88 (m, 3H ), 7.09-7.36 (m, 
4H, Ar-H), 7.56 (d, J=9, 2H ), 9.14 (s,1H);  
MS (EI) m/z: 310 (M+1). Anal.Calcd.for 
C20H25N3O2: C,70.77; H, 7.42; N,12.38. 
Found: C, 72.97; H, 7.40; N, 13.45.        
 
2-[4-(4-Methylphenyl) piperazin-1-yl]-N-
phenylacetamide (3c)  
 
Yield: 56%; m.p.: 109-111 
o
C; IR (KBr, cm
-1
): 
3307, 3016, 2825, 1681, 1238, 1017, 759;          
1
H NMR (300 MHz; CDCl3 δ): 2.28 (s, 3H), 
2.79 -2.82 (m, 4H), 3.11-3.32 (m, 4H), 3.22 ( 
s, 2H, COCH2), 6.80-6.87  (m, 3H ), 7.08-7.36 
(m, 4H, Ar-H), 7.56 (d, J=8.1, 2H ), 9.15 (s, 
1H);
 
MS (EI) m/z: 310 (M+1). Anal.Calcd.for 
C19H23N3O: C, 73.76; H, 7.49; N, 13.58. 
Found: C, 73.28; H, 7.38; N, 13.43.        
 
2-[4-(2-Methoxyphenyl) piperazin-1-yl]-N-
phenylacetamide (3d)  
 
Yield: 52%; m.p.: 119-120 
o
C; IR (KBr, cm
-1
): 
3309, 3013, 2831, 1681, 1237, 1032, 762;         
1
H NMR (300 MHz; CDCl3 δ): 3.87 (s, 3H), 
2.83-2.98 (m, 4H), 3.15-3.31 (m, 4H), 3.21 ( 
s, 2H, COCH2), 6.87 - 6.96 (m, 3H, Ar-H), 
7.00-7.36 (m, 4H, Ar-H), 7.57 (d, J=8.1, 2H ), 
9.19 (s,1H); MS (EI) m/z: 326 (M+1). 
Anal.Calcd.for C19H23N3O: C, 70.13; H, 7.12; 
N, 12.91. Found: C, 70.19; H, 7.10; N, 12.87.       
 
2-[4-(3-Methoxyphenyl) piperazin-1-yl]-N-
phenylacetamide (3e)  
 
Yield: 48%; m.p.: 86-88 
o
C; IR (KBr, cm
-1
): 
3309, 3013, 2831, 1681, 1237, 1032, 762;             
1
H NMR (300 MHz; CDCl3 δ): 3.87 (s,3H), 
2.83 -2.98 (m, 4H), 3.15-3.31 (m, 4H), 3.21 ( 
s, 2H, COCH2), 6.87 - 6.96 (m, 3H, Ar-H), 
7.00-7.36 (m, 4H, Ar-H), 7.57 (d, J=8.1, 2H ), 
9.19 (s,1H);
 
MS (EI) m/z: 326 (M+1). 
Anal.Calcd.for C19H23N3O: C, 70.13; H, 7.12; 
N,12.91. Found: C, 70.08; H, 7.07; N, 12.86.       
 
2-[4-(4-Methoxyphenyl) piperazin-1-yl]-N-
phenylacetamide (3f)  
 
Yield: 45%; m.p.: 95-98 
o
C; IR (KBr, cm
-1
): 
3309, 3013, 2831, 1681, 1237, 1032, 762;             
1
H NMR (300 MHz; CDCl3 δ): 3.78 (s, 3H), 
2.81 -2.97 (m, 4H), 3.15-3.32 (m, 4H), 3.22 ( 
s, 2H, COCH2), 6.80 - 6.95 (m, 3H, Ar-H), 
7.10-7.36 (m, 4H, Ar-H), 7.59 (d, J=9, 2H ), 
9.19 (s,1H); MS (EI) m/z: 326 (M+1). 
Anal.Calcd.for C19H23N3O: C, 70.13; H, 7.12; 





Yield: 52%; m.p: 126-127 
o
C; IR (KBr, cm
-1
): 
3311, 3013, 2829, 1683, 1238, 1015, 758;          
1
H NMR (300 MHz; CDCl3 δ): 2.77 -2.80 (m, 
4H), 3.26-3.29 (m, 4H), 3.21 ( s, 2H, COCH2), 
6.79 - 6.90 (m, 3H, Ar-H), 7.10-7.37 (m, 4H, 
Ar-H), 7.58 (d, J=9, 2H ), 9.08 (s, 1H);                
MS (EI) m/z: 330 (M+1). Anal.Calcd.for 
C18H20ClN3O: C, 65.55; H, 6.11; N, 12.74. 
Found: C, 65.40; H, 6.09; N, 12.69.  
 
2-[4-(3-Chlorophenyl) piperazin-1-yl]-N-
phenylacetamide (3h)  
 
Yield: 57%; m.p.: 104-105 
o
C; IR (KBr, cm
-1
): 
3311, 3013, 2829, 1683, 1238, 1015, 758;         
1
H NMR (300 MHz; CDCl3 δ): 2.77 -2.80 (m, 
4H), 3.26-3.29 (m, 4H), 3.21 ( s, 2H, COCH2),      
6.79 - 6.90 (m, 3H, Ar-H), 7.10-7.37 (m, 4H, 
Ar-H), 7.59 (d, J=9, 2H ), 9.08 (s, 1H);                
MS (EI) m/z: 330 (M+1). Anal.Calcd.for 
C18H20ClN3O: C, 65.55; H, 6.11; N, 12.74. 





Yield: 54%; m.p.: 106-107 
o
C; IR (KBr, cm
-1
): 
3307, 3016, 2829, 1682, 1219, 1016, 766;         
1
H NMR (300 MHz; CDCl3 δ): 2.63-2.83 (m, 
4H), 3.18-3.32 (m, 4H), 3.22 ( s, 2H, COCH2), 
6.88-6.92 (m, 3H ), 7.10-7.37 (m, 4H, Ar-H), 
7.56 (d, J=9, 2H ), 9.12 (s,1H);
 
MS (EI) m/z: 
314 (M+1). Anal.Calcd.for C18H20FN3O: C, 
68.99; H, 6.43; N, 13.41. Found: C, 68.03; H, 
6.35; N, 13.21. 
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Yield: 58%; m.p.: 168-169 
o
C; IR (KBr, cm
-1
): 
3307, 3016, 2829, 1682, 1219, 1016, 766;         
1
H NMR (300 MHz; CDCl3 δ): 2.59-2.82 (m, 
4H), 3.24 (s, 2H, COCH2), 3.48-3.52  (m, 4H), 
6.84 (d, J=7.6,1H ), 7.11-7.16 (m, 2H, Ar-H), 
7.26-7.58 (m, 3H, Ar-H), 7.69 (d, J=7.8, 2H ), 
8.13 (d, J=9.3,1H), 9.14 (s, 1H);
 
MS (EI) m/z: 
341 (M+1). Anal.Calcd.for C18H20N4O3: C, 
63.52; H, 5.92; N, 16.46. Found: C, 63.35; H, 
5.78; N, 16.38. 
 
Aniline (1) was converted to 2-chloro-N-
phenylacetamide (2) by treating with 
chloroacetylchloride in dichloromethane. The 
IR spectrum of compound (2) showed 





H NMR spectrum exhibited a 
broad singlet due to NH group at 8.24. The 
final target compounds 2–[4-(arylsubstituted) 
piperazin-1-yl]-N-phenylacetamides (3a-j) 
were prepared by coupling the 2-chloro-N-
phenylacetamide (2) with appropriate 
phenylpiperazine in acetonitrile in the 
presence of K2CO3 and KI. All the target 
compounds (3a-j) were obtained in good 
yield (45-66%) and characterized by 
analytical and spectroscopic methods as 
described. Mass spectra of newly 
synthesized compounds showed M+1 peak.  
 
The results from the pharmacological 
evaluation of the target compounds are 
shown in Figures 2 - 4. The test compounds 
(3a-j) produced statistically significant 
reversal of apomorphine- induced mesh 
climbing behaviour; 5-hydroxytryptophan (5-
HTP) induced head twitches behaviour and 




Arylpiperazine derivatives display diverse 
pharmacological activity which can be 
mediated by different subpopulations of 
serotonin (5-HT), dopamine and adrenergic 
receptors [15]. In view of the DA-5-HT 



































Figure 2: The effect of synthesized compounds 
(3a-j) on the apomorphine-induced climbing 
behaviour. Each column represents the mean ± 
SEM of climbing score (n = 6) assessed at 5 min 
intervals for 20 min, starting 10 min after 














































Figure 3: The effect of synthesized compounds 
(3a-j) on the 5-HTP-induced head twitches 
behavior. Each column represents the mean 
±SEM of total head twitches score for (n = 6) 
assessed at 10-min intervals for 30 min, starting 
20 min after the 5-HTP treatment.  
 
 
Figure 4: The effect of synthesized compounds 
(3a-j) on induction of catalepsy in mice. Results 
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atypical antipsychotic potential [16] in the 
present work, we synthesized 10 new 
arylpiperazines. All the ligands showed 
significant interactions with the D2 and 5-HT2A 
receptors, which were found to be dependent 
fundamentally on the substitution of the N
4
-
aryl group of the piperazine ring.  
 
The compounds (3h, 3g) possessing chloro 
group at ortho and meta positions of aryl 
moiety of piperazine produced a significant 
greater reversal of apomorphine-induced 
climbing behaviour than their methoxy 
analogs (3d, 3e, 3f). A significant reduction in 
activity was observed when nitro group was 
present at para position of aryl moiety (3j). 
Other compounds (3a, 3i, 3b and 3c) showed 
lower efficacy at the D2 receptor. The 
inhibition of 5-HTP induced head twitches 
behaviour (5-HT2A antagonism) study showed 
that methoxy analogs produced significant 
higher activity than chloro analogs. The other 
compounds (3a, 3b, 3c, 3f, and 3g) showed 
lower antagonism of 5-HTP-induced head 
twitches behaviour. The catalepsy results 
showed all the new compounds (3a-j) were 
less cataletogenic than haloperidol. Among 
them, chloro analogs (3h and 3g) exhibited 




A new series of arylpiperazines have been 
synthesized and preliminary pharmacological 
evaluations show their potential antipsychotic 
activity. Among the compounds, 3h displayed 
significant inhibition activity for D2 and 5-HT2A 
receptors and minimum induction of 
catalepsy. Further studies on this lead are 
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